Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn’s Disease: Real-World Data from a German IBD Cohort

Background and Aims: The IL-12/23 inhibitor ustekinumab (UST) opened up new treatment options for patients with Crohn’s disease (CD). Due to the recent approval, real-world German data on long-term efficacy and safety are lacking. This study aimed to assess the clinical course of CD patients under U...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubesch, Alica, Rueter, Laurenz, Farrag, Karima, Krause, Thomas, Stienecker, Klaus, Hausmann, Johannes, Filmann, Natalie, Dignass, Axel, Stein, Jürgen, Blumenstein, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947251/
https://www.ncbi.nlm.nih.gov/pubmed/31817134
http://dx.doi.org/10.3390/jcm8122140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947251/
https://www.ncbi.nlm.nih.gov/pubmed/31817134
http://dx.doi.org/10.3390/jcm8122140

Ejemplares similares